SCHEMBL23482004

SCHEMBL23482004

N#Cc1ccc2cc(CCN3CC4(CCC4)C3)[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 9/20 0.48
DRD2 P14416 8/20 0.48
DRD4 P21917 8/20 0.48
HRH3 Q9Y5N1 3/20 0.44
METTL3 Q86U44 1/20 0.44
METTL14 Q9HCE5 1/20 0.44
MEN1 O00255 1/20 0.43
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KCNH2 Q12809 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
DRD1 P21728 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CHRNA7 P36544 2/20 0.38
PIP5K1C O60331 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23482001 0.84 HRH3 (0.60) DRD3DRD2DRD4HRH3MEN1
SCHEMBL23481976 0.79 METTL3 (0.51) DRD3DRD4HRH3METTL3METTL14
SCHEMBL29965877 0.79 METTL3 (0.51) DRD3DRD4HRH3METTL3METTL14
SCHEMBL23458882 0.73 DRD2 (0.49) DRD3DRD2DRD4MEN1
SCHEMBL29919242 0.73 DRD2 (0.49) DRD3DRD2DRD4MEN1
SCHEMBL31519231 0.72 DRD3 (0.64) DRD3DRD2DRD4METTL3METTL14
SCHEMBL7442607 0.70 DRD2 (0.51) DRD3DRD2DRD4MEN1
SCHEMBL31663252 0.70 DRD2 (0.51) DRD3DRD2DRD4MEN1
SCHEMBL7503276 0.70 DRD2 (0.51) DRD3DRD2DRD4
SCHEMBL9056119 0.70 DRD2 (0.51) DRD3DRD2DRD4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2023-01-05 US disclosed
WO-2021111124-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT DRD3 2700/4885DRD2 4008/4885DRD4 3499/4885
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT DRD3 2700/4885DRD2 4008/4885DRD4 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.